Autolus Therapeutics (NASDAQ:AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, featuring clinicians and investigators who discussed the treatment landscape, real-world experience with the company’s CD19-directed CAR T-cell therapy obe-cel, and ongoing efforts to evaluate the product earlier in treatment and in pediatric patients. Adult relapsed/refractory ALL: unmet need and where […]